2,010 results on '"Rizzo Manfredi"'
Search Results
2. Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group
3. Circadian rhythms and cancer: implications for timing in therapy
4. Hepatic effects of GLP-1 mimetics in diabetic milieu: A mechanistic review of involved pathways
5. Triglyceride-glucose index (TyG) as a novel biomarker in the era of cardiometabolic medicine
6. Doxorubicin and cyclophosphamide mode of chemotherapy–related cardiomyopathy: Review of preclinical model
7. The Effect of Sodium–Glucose Cotransporter Inhibitors on Renal Function as Adjunctive to Insulin in Adults with Type 1 Diabetes: An Updated Multilevel Meta-analysis of Randomized Controlled Trials
8. New-Onset Diabetes Mellitus in COVID-19: A Scoping Review
9. Diabetic cardiomyopathy: pathophysiology, imaging assessment and therapeutical strategies
10. Cilostazol for the treatment of distal symmetrical polyneuropathy in diabetes mellitus: Where do we stand?
11. Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Acute Coronary Syndrome: A Modern Cinderella?
12. The importance of arterial stiffness in pediatric patients with type 1 diabetes mellitus: What's new?
13. Emerging treatment strategies for polycystic ovary syndrome women with obesity: Focus on glucagon-like peptide-1 receptor agonists
14. Impact of different hormones on the regulation of nitric oxide in diabetes
15. Correction to: New-Onset Diabetes Mellitus in COVID-19: A Scoping Review
16. Can tirzepatide untie the Gordian knot of eating disorders among individuals with type 2 diabetes and obesity?
17. The effect of SGLT2 inhibitors and GLP1 receptor agonists on arterial stiffness: A meta-analysis of randomized controlled trials
18. Maturity-onset diabetes of the young (MODY) - in search of ideal diagnostic criteria and precise treatment
19. Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP).
20. Unraveling the tumor microenvironment: Insights into cancer metastasis and therapeutic strategies
21. Managing cardio-renal-metabolic risk in patients with type 2 diabetes: the role of finerenone
22. Analysis of the therapeutic potential of miR-124 and miR-16 in non-alcoholic fatty liver disease
23. Neurological Consequences, Mental Health, Physical Care, and Appropriate Nutrition in Long-COVID-19
24. Clinical Efficacy of Proprotein Convertase Synthase Kexin Type 9 Inhibition in Persons with Diabetes Mellitus
25. Clinical impact of genetic testing for lipid disorders
26. Understanding the mechanisms mediating cardio-renal benefit of empagliflozin in type 2 diabetes mellitus
27. Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials
28. Semaglutide in Obesity: Unmet Needs in Men
29. Absolute Hyperglycemia versus Stress Hyperglycemia Ratio for the Prognosis of Hospitalized Patients with COVID-19 in the First Months of the Pandemic: A Retrospective Study
30. Effect of semaglutide versus other glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors in patients with type 2 diabetes: A systematic review and meta-analysis of head-to-head, phase 3, randomized controlled trials
31. GLP-1 receptor agonists and SGLT2 inhibitors: The need to shed light on their safety risks real dimension and possible mechanisms
32. PUFA treatment in patients with gestational diabetes mellitus: Lights and shadows
33. The role of atherogenic lipoproteins in diabetes: Molecular aspects and clinical significance
34. ORal anticoaGulants in diAbetic and Nondiabetic patients with nOn-valvular atrial fibrillatioN (ORGANON)
35. The effect of Spirulina supplementation on lipid profile: GRADE-assessed systematic review and dose-response meta-analysis of data from randomized controlled trials
36. The effect of SGLT2 inhibitors, GLP1 agonists, and their sequential combination on cardiometabolic parameters: A randomized, prospective, intervention study
37. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)
38. Metformin in SARS-CoV-2 infection: A hidden path – from altered inflammation to reduced mortality. A review from the literature
39. The Dual Pandemics of COVID-19 and Obesity: Bidirectional Impact
40. The effect of statin therapy in combination with ezetimibe on circulating C-reactive protein levels: a systematic review and meta-analysis of randomized controlled trials
41. Nutraceuticals and Cardiovascular Disease
42. Future Perspectives in Nutraceutical Research
43. Critical questions in diabetes management: What are the most compelling challenges and how can we handle them?
44. Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health
45. Post-COVID syndrome, inflammation, and diabetes
46. Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group
47. Statins and angiogenesis in non-cardiovascular diseases
48. Dietary patterns in non-alcoholic fatty liver disease (NAFLD): Stay on the straight and narrow path!
49. Quality of Life in People with Diabetes Mellitus and Unilateral Transtibial Amputation - Aspects of Using the Berg Balance Scale.
50. Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.